Tetra Bio-Pharma Signs Co-development and Distribution Partnership Term Sheet
Momentum Public Relations
Press Release: March 8 2018
Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce it has signed a co-development and distribution partnership term sheet with a major specialty healthcare distributor.
The finalization of the term sheet follows Tetra’s September 20th, 2017 Letter of Intent for a co-development and distribution partnership with the same privately held company in the specialty healthcare market. The company has a pan-Canadian distribution network that reaches up to 7000 specialized healthcare professionals. Through their distribution channel, they have access to more than 3000 specialized healthcare businesses in Canada and already work with a worldwide network of partners.
Partnership highlights
- In order to maximize both marketing and revenue impact, Tetra and its partner have agreed to launch all products at the same time, once the regulatory framework has been established by Health Canada following the legalization of cannabis. This includes cannabinoid-based as well as non-cannabinoid-based products. Both companies are confident that this strategy will solidify the brand awareness of Tetra’s partner in this new product line. The timing of the original LOI was for the commencement of revenue in Q1 2018. Tetra and its partner are now revising that date to Q4 2018.
- Both Tetra and its partner will agree to a clinical trial plan, with Tetra owning and maintaining the right to use the data gathered from the trial(s) for its own regulatory and commercial efforts in its own, non-competitive Fields of Use.
- Tetra will develop a line of private label products for its partner, the products will be distributed under the partner’s brand.
Management Statement
“We are very pleased to sign this term sheet as it solidifies the elements of the LOI outlined in September. We are continually striving and working hard every day to both solidify and grow Tetra as a major player in cannabinoid pharma and this is yet again a step in that direction. I am excited to continue to build on the momentum that we have going for us now and throughout 2018,” says Bernard Fortier, CEO of Tetra.
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.
More information at: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a license for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
(438) 899-7575
For investors information, please contact:
investors@tetrabiopharma.com
(438) 504-5784
- Published in Tetra Bio Pharma
ProSmart Accelerates Development of Its Next-Generation Sports Community Platform
Momentum Public Relations
Press release: March 8 2018
ProSmart Enterprises Inc. (TSXV:PROS) (“ProSmart” or the “Company”), a global online network, connecting sports fans, teams and brands, is pleased to announce it has entered into an agreement (the “Agreement”) with Firestitch Inc. (“Firestitch”) to accelerate development of its next generation sports community platform. The new features and functionality will help drive user growth, as well as provide additional partner services that will enhance revenue potential for the Company. ProSmart’s online network already has industry-leading advantages, such as sports-training, coaching and team management content created exclusively by Hall-of-Famers, Olympic and Professional athletes and coaches. In the last two years, ProSmart users amongst sports fans, players and coaches has grown by 1000% and now spans more than 100 countries. The Company also recently announced a strategic acquisition in China as the first step in an aggressive expansion into the rapidly-growing Chinese sports market.
ProSmart’s new online networking and community engine will dramatically expand functionality and value for users, while adding new, potential revenue streams and increasing diversity, customization and new publishing tools for partners. It will also provide seamless integration of new technologies (organically built, licensed or acquired) and allow better data capture and analysis. This will facilitate greater revenue generation per user over a longer period of time, which means a high lifetime value per user.
Says Alan Schuler, Co-founder and CEO of ProSmart: “We have been working closely with our users, as well as new partners like the Vancouver Canucks and many other professional sports teams and franchises that have expressed strong interest in partnering with us. This has helped us build a crystal-clear understanding of the enhancements they want to see in the ProSmart online network and marketplace engine. This agreement puts us on a greatly-accelerated path to our next generation platform so we are excited to work with Firestitch. Once complete, these enhancements will unlock a number of market opportunities. We are very pleased that Firestitch recognizes our market potential and is taking a significant part of their compensation in shares.”
About Firestitch
Firestitch is a highly-respected Toronto-based web and mobile app development company (https://firestitch.com/). With years of experience, technical expertise and proficient workforce to back their reputation, Firestitch has been able to create a niche in this extremely competitive industry by delivering incomparable results and efficient services each time.
The Agreement has a 12-month term (which may be terminated by the Company upon 30 days written notice) and is renewable at the mutual-agreement of both parties. Over the four phases of the project, Firestitch will be paid up to $650,000 with 70% paid as cash and, subject to approval of the TSX Venture Exchange (the “TSXV”), 30% satisfied by way of common shares of the Company. The number of common shares to be issued shall be equal to the value of the equity portion divided by the price of the shares, which will be calculated as the average price per share on the TSXV for the five days subsequent to the end of the monthly period (the “Deemed Price”). In addition, Firestitch is eligible for a completion bonus upon completing the project calculated based on 1/3 of the equity portion received and will be satisfied by way of common shares issued at the Deemed Price. Firestitich will also be reimbursed for reasonable out-of-pocket expenses. Firestitch does not currently hold any common shares of the Company and does not have any other direct or indirect interests in the Company. The Agreement and the issuance of common shares is subject to the approval of the TSXV.
Restricted Share Unit (“RSU”) Awards
In addition, 500,000 RSUs are being awarded to a director and an employee pursuant to the Company’s RSU plan. The RSUs shall vest according to defined performance conditions being met. All RSUs will be subject to applicable securities laws hold periods. The award of RSUs remains subject to approval of the TSXV.
On behalf of ProSmart Enterprises Inc.
Alan Schuler
Co-Founder & Chief Executive Officer
About ProSmart Enterprises Inc.
ProSmart (TSX-V:PROS) is a global online network connecting sports fans, teams and brands and is an emerging leader in sports content marketing through online tools and mobile apps. ProSmart works with over 1,500 governing bodies in more than 100 countries and provides unprecedented access to the $1.3 trillion sports market through its proprietary marketplace engine. ProSmart is also the first-and-only company to provide educational content created exclusively by hall-of-fame and professional athletes, which has been a key driver in building the company’s online network and connecting with youth, amateur and professional sports fans and players. ProSmart is a publicly traded company listed on the TSX-V.
For more information on ProSmart and its platforms, please visit the following links:
ProSmart Inc.: http://prosmartinc.com
RosterBot Inc.: http://rosterbot.com
ProSmart Hockey: http://prosmarthockey.com
ProSmart Football (Soccer): http://prosmartfootball.com
Stay connected with ProSmart by following us on:
LinkedIn (www.linkedin.com/company/prosmartsports)
CrunchBase (www.crunchbase.com/organization/prosmart-sports-development-inc)
AngelList (www.angel.co/prosmart-sports-development)
For further information please contact:
Ty Summach, Chief Operating Officer
t: 1-844-927-6278 ext. 103
e: investment@prosmartsports.com
The shares of ProSmart Enterprises Inc. trade publicly on the TSX Venture Exchange under the symbol TSXV:PROS.
“Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.”
To view the associated document to this release, please click on the following link:
public://news_release_pdf/ProSmart03082018.pdf
To view the original release, please click here
Source: ProSmart Enterprises Inc. (TSX Venture:PROS, FWB:1R6)
To follow ProSmart Enterprises Inc. on your favorite social media platform or financial websites, please click on the icons below.
- Published in Prosmart Enterprises
Following a successful year, DIAGNOS Announces a One-Year Agreement in United Arabs Emirates with a Major Pharmaceutical Company
Momentum Public Relations
Press Release: March 7 2018
DIAGNOS Inc. (“DIAGNOS” or “the Corporation”) (TSX-V:ADK) (OTCQB:DGNOF), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces today a follow-up contract by signing a turnkey one-year screening contract in United Arabs Emirates.
So far, DIAGNOS’ healthcare services have been rendered in 16 countries worldwide. During the period covered by the agreement, we estimate that an additional 2,500 patients will be screened in UAE using our CARA platform.
“We are excited to continue our collaboration with this large pharmaceutical company. More and more we, DIAGNOS and our pharmaceutical partner, are working at educating governments around the world to our Wellness Program (CARA) and demonstrating the benefits and cost savings that can be attained from it. We are continuing to implement our growth strategy with our existing pharmaceutical partner,” said Yves-Stéphane Couture, DIAGNOS Vice-President of sales.
About CARA
CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care (POC) and comprises: image upload, image enhancement automated pre-screening, grading by a specialist, and referral to a specialist. CARA’s Artificial Intelligence, based on our FLAIRE technology, image enhancement algorithms make standard retinal images sharper, clearer, and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients, in real time and has been approved by regulatory authorities including Health Canada, US Food and Drug Administration, the European Union and others.
Additional information is available at www.diagnos.ca and www.sedar.com.
For further information, please contact:
Mr. André Larente, President | Daniel Renaud or Thomas Renaud, Managing Directors |
DIAGNOS Inc. | Arrowhead Business and Investment Decisions, LLC |
Tel: 450-678-8882 ext. 224 | Tel: +1 212 619 6889, ext. 7010 |
alarente@diagnos.ca | diagnos@arrowheadbid.com |
This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
- Published in Diagnos
Hillcrest Petroleum Saskatchewan Production Update
Momentum Public Relations
Press Release: February 6 2018
Hillcrest Petroleum Ltd. (the ” Company ” or ” Hillcrest “) is pleased to provide the following update on the Company’s development and production operations in Saskatchewan.
Hillcrest previously announced that production from the 16-13 well was restored in early January of this year. Reported daily production from the well was approximately 19 barrels of oil per day (bopd) during January, increasing slightly to 20 bopd during February. Cumulative reported oil production from the well was approximately 1160 barrels to the end of February, which is in line with the Company’s expectations.
Hillcrest also undertook a well work-over operation on the nearby 07-13 well, including production tubing replacement and installation of a new down-hole pump. The 07-13 well was turned over to production on February 19 th and has averaged approximately 90 barrels of fluid per day (bfpd), with the reported oil cut slowly increasing from 5% to 20% through to the end of February. With the relatively high total fluid production from the well and the increasing oil cut as production stabilizes, reported daily oil production averaged approximately 18 bopd during the last four days of February. The Company does expect to see an increase in the oil cut from the 07-13 well during March.
Pursuant to the agreement with Westcore Energy Ltd. (“Westcore”), Hillcrest earns a 50% working interest in the production from the wells by providing financial and technical support to the approved workover program.
The Company is pleased with the results of the development and production operations to date, particularly in light of the cold temperatures and harsh operating conditions in the area during late December and into January and February.
T he well workover program is a first step towards a contemplated larger acreage development and drilling program agreement under review between Westcore and its partners. Westcore owns and operates two large acreage positions in the Province of Saskatchewan and is in discussions with Hillcrest whereby the Company will have the option to participate in a development program. Hillcrest will advise our shareholders if and when formal agreements are signed and in place.
For more information on Hillcrest Petroleum Ltd, contact on Currie toll free at 1-855-609-0006 or visit the Company’s website at www.hillcrestpetroleum.com
ON BEHALF OF THE BOARD
Donald Currie
Chief Executive Officer and Director
Cautionary Statement Regarding “Forward-Looking” Information
Some of the statements contained in this news release are forward-looking statements and information within the meaning of applicable securities laws. Forward-looking statements and information can be identified by the use of words such as “expects”, “intends”, “is expected”, “potential”, “suggests” or variations of such words or phrases, or statements that certain actions, events or results “may”, “could”, “should”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements and information are not historical facts and are subject to a number of risks and uncertainties beyond the Company’s control. Actual results and developments are likely to differ, and may differ materially, from those expressed or implied by the forward-looking statements contained in this news release. Accordingly, readers should not place undue reliance on forward-looking statements. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements, except as may be required by law.
Neither TSX Venture Exchange nor its Regulations Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
- Published in Uncategorized
Tetra Bio-Pharma Takes First Steps into European Medical Cannabis Market
Momentum Public Relations
Press Release: March 6 2018
Tetra Bio-Pharma Inc. (“Tetra” or the “Corporation”) (TSX VENTURE:TBP)(OTCQB:TBPMF) announced today that its partner PS Innovations will be seeking CE Marking for its Rx Princeps™ Inhalation Device, thereby opening the door to Tetra’s commercialization efforts in Europe.
Tetra’s development and manufacturing partner, PS Innovations, will be seeking CE Marking for Tetra’s Rx Princeps™ Inhalation Device, which is used in conjunction with a dried loose cannabis, such as Rx Princeps™, to provide relief for advanced cancer pain and non-cancer pain patients.
Rx Princeps™ is a unique blend of 3 strains of medical cannabis. Its production has been standardized in order to ensure a lot-to-lot consistent composition in its active ingredients (THC and CBD). Rx Princeps™ is composed of the same medical cannabis blend used to produce PPP001, the lead product in Tetra’s pipeline of five cannabinoid-based prescription drugs seeking Health Canada and FDA approval in Canada and the United States.
“CE marking” is the process that guarantees a product’s conformity to the European regulations and is required to allow Tetra to commercialize and trade on the European and European Economic Area markets. Under the European regulation, Rx Princeps™ Inhalation Device will be considered as a Class 1 Medical Device.
“This is significant for Tetra since there are a number of European countries, with Germany at the forefront, where medical cannabis has been legalized,” said Bernard Fortier, Tetra’s CEO.
The annual potential estimate for the medical cannabis European market value is EUR35.7b, according to the European cannabis report from a Prohibition Partners November 2017 report. In the US, the consumption devices market grew 116.5% in 2016 (year over year growth, New Frontier data report 2016).
“We know that more than half the people who consume cannabis choose to smoke it,” said Mr. Fortier. “This first step into Europe with a strong partner like PS Innovations solidifies our strategic focus on global expansion and potentially offers the European medical community and their patients the most innovative therapeutic options.”
PS Innovations will ensure that the Rx Princeps™ Inhalation Device meets all the relevant Essential Requirements of the European Medical Device Directive and then register the product with the Competent Authority and affix the CE marking.
About PS Innovations:
PS Innovations was created in 2017 to bring new devices for the use of Cannabis products, and the creation of machinery dedicated to the manufacture of Cannabis based dosage forms. Current devices on the market today are designed for the use of tobacco, and not cannabis derived products. Cannabis is unique in many ways, and does not always behave in the manner that tobacco products do. PS Innovations has been able to bring to the market a Class I medical device, namely an inhalation device (pipe) specific to the ACMPR [Access to Cannabis for Medical Purposes Regulations] use of dry loose cannabis.
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.
More information at: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Corporation believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Corporation’s ability to control or predict, that may cause the actual results of the Corporation to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, failure to obtain sufficient financing to execute the Corporation’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Corporation’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Corporation’s public disclosure record on file with the relevant securities regulatory authorities. Although the Corporation has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed The forward-looking statements included in this news release are made as of the date of this news release and the Corporation does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
investors@tetrabiopharma.com
1 (438) 899-7575
- Published in Tetra Bio Pharma
Auxico Announces the Acquisition of Thirteen Properties in Colombia and First Test Results
Momentum Public Relations
Press Release: March 5 2018
Auxico Resources Canada Inc. (CSE:AUAG) is pleased to announce the acquisition of thirteen (13) properties located 75 km southwest of the city of Bogota, Colombia. These properties represent a total of 65,000 hectares with each property averaging approximately 5,000 hectares. This area is known for high-grade gold and cobalt, as well as other base metals.
Joel Scodnick, the Company’s consulting professional geologist, visited the properties and validated the metal content from the samples. We are pleased to announce the first results of the Restopo property where volcanic boulders up to 1 ton in size, yielded results of up to 16.3% copper. A certified technician form Symtek, affiliated with SGS Laboratories in Colombia, analyzed the samples.
Further results from all of the properties are expected this week.
Qualified Person
This news release was reviewed and approved by Joel Scodnick, P.Geo., an independent consultant to Auxico, in his capacity as a Qualified Person, as defined by National Instrument 43-101.
ON BEHALF OF THE BOARD OF DIRECTORS
Mark Billings
President, Auxico Resources Canada Inc.
mb@auxicoresources.com
Cell: +1 514 296 1641
About Auxico Resources Canada Inc.
Auxico Resources Canada Inc. (“Auxico”) in a Canadian company that was founded in 2014 and based in Montreal. Auxico is engaged in the acquisition, exploration and development of mineral properties in Mexico. The Company has a 100% interest in the Zamora Silver-Gold Property in Sinaloa, Mexico. Auxico will continue to identify and potentially acquire additional property interests and conduct exploration and evaluation of these properties to assess their potential.
The Canadian Securities Exchange (CSE) has not reviewed and does not accept responsibility for the adequacy or the accuracy of the contents of this release.
- Published in Uncategorized
Relevium Appoints Mr. Didier Martin as Blockchain Lead Expert
Momentum Public Relations
Press Release: March 5 2018
Relevium Technologies Inc. (TSX VENTURE:RLV)(OTCQB:RLLVF) and (FRANKFURT:6BX) (the “Company” or “Relevium”), is pleased to announce it has appointed Mr. Didier Martin as special advisor and project leader for the Company’s current and future Blockchain projects.
Mr. Didier Martin joins the company effective immediately in his advisory capacity to provide technical leadership over the Company’s current and future Blockchain Technology projects, including advising on all strategic aspects of a potential Token Security Offering (TSO), the integration and positioning of the technology into the Tagspire joint venture and developing use cases for Relevium including the development of a supply chain security private Blockchain solution for the company’s online business.
Aurelio Useche, CEO stated: “In a growing and competitive space like health and wellness, we need to be nimble and able to adopt new technology. Blockchain and Artificial Intelligence are examples of useful and applicable technologies we can integrate to provide a competitive advantage to our business”. Mr. Useche stated further: “We can either take a lead and open ourselves today to the blue-sky that these technologies can provide, OR we can become followers and late adopters. The choice to us is very clear”
Mr. Didier Martin serves currently as Lead Expert at Interblockchain.io, a solution capable of interconnecting heterogeneous Blockchain allowing free cryptocurrencies movements between Bitcoin, Bitcoin Cash, Litecoin, Ethereum, Neo, EOS and his experience is well aligned to provide a solid ground for the Company’s plans in this space. Mr. Martin has 30 years’ experience in the management of technology, security and software development. Mr. Martin has also held senior executive roles in several start-ups, public companies and consortiums.
Aurelio Useche, CEO stated: “We are honoured to have Didier as our Blockchain lead expert. Our entire team extends a warm welcome to Mr. Martin and look forward to identifying opportunities and use cases for our business”
The appointment of a Blockchain expert solidifies Relevium’s commitment to accomplish everything set forth in the H2 guidance and to ensure the best talent and partners within the industry, as the Company continues to grow its business.
About Blockchain Technology
Blockchain is a transparent and incorruptible digital ledger that can be applied to any transaction of value. This digital ledger is a dynamic growing list of records (blocks) linked to each other and encrypted for security. In addition to security, Blockchain enables the use of smart contracts, which are self-automated computer programs that can carry out the terms of any contract or transaction. Blockchain is the underlying technology behind cryptocurrencies.
“…the most critical area where Blockchain helps is to guarantee the validity of a transaction by recording it not only on a main register but a connected distributed system of registers, all of which are connected through a secure validation mechanism.” Ian Khan, TEDx Speaker, Author and Technology Futurist
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will obtain stock exchange approval of the Offering, the proposed acquisition will occur as anticipated, that the Company will raise sufficient funds, and that the Company will obtain all requisite approvals of the acquisition. These forward- looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed acquisitions may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds under the Offering. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche, President and CEO
Relevium Technologies Inc.
+1.888.528.8687
investors@releviumcorp.com
www.releviumtechnologies.com
- Published in Relevium Technologies
Tetra Bio-Pharma Announces Closing of Bought Deal Financing
Momentum Public Relations
Press Release: February 5 2018
Tetra Bio-Pharma Inc. (“Tetra” or the “Corporation”) (TSX-V:TBP) (OTCQB:TBPMF), is pleased to announce it has closed its short form prospectus offering, on a bought deal basis, including the exercise in full of the underwriter’s over-allotment option. A total of 11,500,000 units (the “Units”) of the Corporation were sold at a price of $1.00 per Unit, for aggregate gross proceeds of $11,500,00 (the “Offering”).
Each Unit consisted of one common share of the Corporation and one common share purchase warrant. Each Warrant will entitle the holder thereof to purchase one common share of the Corporation at a price of $1.30 until March 5, 2021. The Offering was underwritten by Echelon Wealth Partners Inc.
The Corporation intends to use the net proceeds from the Offering to continue the development of its clinical program aimed at bringing novel drugs and treatments to patients and their healthcare providers, to repay indebtedness of the Corporation, and for working capital and general corporate purposes.
“We are extremely pleased to have worked with Echelon Wealth Partners in this financing . As we are about to initiate our Health Canada approved phase 3 registration trial for our lead drug candidate, PPP001, for late stage cancer patients, the proceeds from this Offering will enable Tetra to continue, and potentially accelerate some of the key development projects in our pipeline. This is another milestone in working towards becoming the first biopharmaceutical company in the world to get a smokable dried cannabis product approved as a prescription drug by Health Canada, the FDA and other regulatory agencies around the world,” stated Bernard Fortier, CEO of Tetra.
The securities mentioned herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act“) or any U.S. state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws.
This press release does not constitute an offer to sell or a solicitation of any offer to buy the securities in the United States, in any province or territory of Canada or in any other jurisdiction. There shall be no sale of the securities in any jurisdiction in which an offer to sell, a solicitation of an offer to buy or sale would be unlawful.
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX-V:TBP) (OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.
More information at: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
For further information, please contact Tetra Bio-Pharma Inc.
Bernard Lessard, MBA, CPA, CMA
Chief Financial Officer
bernard.lessard@tetrabiopharma.com
438 899 7575 ext.207
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Corporation believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Corporation’s ability to control or predict, that may cause the actual results of the Corporation to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, failure to obtain sufficient financing to execute the Corporation’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Corporation’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Corporation’s public disclosure record on file with the relevant securities regulatory authorities. Although the Corporation has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed The forward-looking statements included in this news release are made as of the date of this news release and the Corporation does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
- Published in Tetra Bio Pharma
ProSmart to Acquire DL Hockey in China
Momentum Public Relations
Press Release: March 5 2018
ProSmart Enterprises Inc. (TSXV:PROS) (“ProSmart” or the “Company”), a global online network, connecting sports fans, teams and brands, announces it has entered into a binding agreement (the “Agreement”) to acquire all of the issued and outstanding shares of DL Hockey Consulting (Shenzhen) Limited and DL Hockey Consulting Limited (combined, “DL Hockey” and the “Acquisitions”). DL Hockey operates a hockey club and skills camps in China, where 650 skating rinks are being built as part of its winter sports development plan in the run up to their hosting of the 2022 Winter Olympics. Of additional note, DL Hockey has built a national network of key hockey development relationships in China, which is one of the world’s largest and fastest-growing sports markets.
News Highlights
- ProSmart is acquiring DL Hockey – a well-established brand and operator of a hockey club and skills camps in China
- China is building 650 skating rinks in preparation for the 2022 Olympic Winter Games
- Chinese sports industry estimated to more than triple its US$223B (2016) value by 2025 (Bank of China report, 2017)
- Acquisition will provide ProSmart with instant access to China’s hockey community and industry as part of a trusted, established brand
ProSmart, which provides unprecedented access to the $1.3 trillion sports industry, works with over 1,500 governing bodies in more than 100 countries. With this acquisition, the Company will have successfully expanded its network into the Chinese sports market which, according to a 2017 Bank of China report, was estimated to be worth 1.5 trillion yuan (US$223 billion) in 2016 and on track to reach 5 trillion yuan by 2025.
Alan Schuler, Co-founder and CEO, states, “This is a highly-strategic deal which comes at a time when China’s Winter Olympics development plans have sent the sports industry into overdrive. DL Hockey has a strong, established presence in China and has built a tremendous reputation. This acquisition allows us to quickly and seamlessly integrate with China’s hockey community and industry which is expanding at an incredible rate. With over 65% of the population identifying themselves as sports fans, China has one of the largest sports markets in the world. With ProSmart’s global online network, unique content and unprecedented marketing platform, this acquisition has the potential to deliver considerable value for ProSmart shareholders and is part of our push into the Chinese market.”
ProSmart will retain the DL Hockey School brand and run hockey development programs under this banner. The company is now well positioned to leverage the momentum and credibility built by DL Hockey to expand ProSmart programs nationally in conjunction with the rapidly-growing community of rink developers and burgeoning hockey markets in China.
Says Doug Lynch, founder of DL Hockey, “I am extremely excited about joining the ProSmart family. The vision that Alan and senior management have created, aligns with my beliefs on the importance of youth sports for children of all ages. In a short time, I have truly connected with the players in our club, their families, as well as the Chinese culture. I remain dedicated to growing, not only hockey, but all other sports in China. The ProSmart learning platform is revolutionizing youth sports as well as training youth coaches and I feel grateful to be a part of the journey.”
About the Acquisitions
DL Hockey was founded by, and is wholly-owned by Doug Lynch, a former professional hockey player. DL Hockey has developed a national network of key hockey development relationships dedicated to the growth of hockey in China. With an impeccable reputation for operating highly effective hockey development camps, DL Hockey is a leading hockey growth organization in China.
Upon completion of the Acquisitions, Doug Lynch will join ProSmart as Vice President of Business Development in China and will be responsible for strategic leadership and operations of the Company’s China operations, including the growth of DL Hockey Schools nationally. Part of his compensation will be tied to a number of pre-established performance metrics.
Doug Lynch will collaborate with arena development partners to position ProSmart as the leading hockey development system in China. He will also collaborate with sponsors, brands, growth partners, and develop revenue opportunities designed to increase the growth of DL Hockey, ProSmart’s Chinese brand and ProSmart Enterprises Inc., its Canadian parent company.
The Agreement was signed on February 27, 2018 and the Acquisitions are expected to close on March 15, 2018 (“Closing”) and is subject to the approval of the TSX Venture Exchange and ProSmart’s Board of Directors. The purchase price is US$86,250 payable in ProSmart common shares (“Shares”) at a Share price equivalent to the ten (10) trading day volume-weighted average closing price of the Shares on the TSX Venture Exchange immediately prior to the public announcement of this Agreement. The Shares will be held in escrow or in a pooling agreement and will be released in equal quarterly installments over the 36 months following closing of the acquisition. The first installment will be released at Closing. This is an arms-length transaction with no finder’s fees involved.
Further Information About the Chinese Sports Market
The Chinese sports market is a massive opportunity for ProSmart:
- In a national strategy spearheaded by the General Administration of Sport, China plans to build 100 towns dedicated as centers of sporting excellence for various disciplines in coming years.
- According to market consultancy, Analysis, the total revenue generated from sponsorship, broadcasting and fan spending on winter sports events is expected to reach 160 billion yuan (US$26 billion) by 2025.
On behalf of ProSmart Enterprises Inc.
Alan Schuler
Co-Founder & Chief Executive Officer
About ProSmart Enterprises Inc.
ProSmart (TSX-V:PROS) is a global online network connecting sports fans, teams and brands and is an emerging leader in sports content marketing through online tools and mobile apps. ProSmart works with over 1,500 governing bodies in more than 100 countries and provides unprecedented access to the $1.3 trillion sports market through its proprietary marketplace engine. ProSmart is also the first-and-only company to provide educational content created exclusively by hall-of-fame and professional athletes, which has been a key driver in building the company’s online network and connecting with youth, amateur and professional sports fans and players. ProSmart is a publicly traded company listed on the TSX-V.
For more information on ProSmart and its platforms, please visit the following links:
ProSmart Inc.: http://prosmartinc.com
RosterBot Inc.: http://rosterbot.com
ProSmart Hockey: http://prosmarthockey.com
ProSmart Football (Soccer): http://prosmartfootball.com
Stay connected with ProSmart by following us on:
LinkedIn ( www.linkedin.com/company/prosmartsports )
CrunchBase ( www.crunchbase.com/organization/prosmart-sports-development-inc )
AngelList ( www.angel.co/prosmart-sports-development )For further investor information please contact:
Ty Summach, Chief Operating Officer
t: 1-844-927-6278 ext. 103
e: investment@prosmartsports.com
The shares of ProSmart Enterprises Inc. trade publicly on the TSX Venture Exchange under the symbol TSXV:PROS.
“Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.”
To view the associated document to this release, please click on the following link:
public://news_release_pdf/ProSmart03052018.pdf
To view the original release, please click here
Source: ProSmart Enterprises Inc. (TSX Venture:PROS, FWB:1R6)
To follow ProSmart Enterprises Inc. on your favorite social media platform or financial websites, please click on the icons below.
- Published in Prosmart Enterprises
Relevium Provides H2 Guidance for Bioganix, Acquisitions and Legal Hemp Derivatives
Momentum Public Relations
Press Release: March 2 2018
Relevium Technologies Inc. (TSX VENTURE:RLV)(OTCQB:RLLVF)(FRANKFURT:6BX) (the “Company” or “Relevium”), is pleased to provide guidance on its strategy for its core e-commerce business for the second half of fiscal year ending June 30, 2018.
Highlights
- Bioganix® strategy and revenue expansion
- Official launch of Planet Hemp products
- Introduction and launch of Heart and Eye Health Omega 7 products
- Guidance on legal hemp derivatives for nutraceutical and skin care
- Launching of first pet care product
- European expansion of Bioganix brand
- Strategy and guidance for actionable M&A opportunities
Bioganix Strategy and Revenue Expansion
The Company has shifted its focus from daily operations optimization to increasing brand value. As such, Bioganix® is undergoing a major brand facelift which will better represent the values presentation and promise to our growing customer base. Words like Credibility, Quality, Trust, Elevated, Accessible, Centered, Confident, Wellness and Self-Actualization will be at the core of the new presentation to the market, with the objective at seeking higher conversion rates and brand loyalty within a more informed and wider audience base.
Relevium has been working with a newly extended supplier base and intends to launch sixteen (16) new products under the Bioganix® product brand before June 30, 2018. These new products will represent the first set of products launched entirely by the Relevium Operations Team since taking control of the business in July of 2017.
Official Launch of Planet Hemp Products
Since signing the exclusive product agreement with Hempco and PlanetHemp, the Company has been working closely with the team at Hempco to launch the PlanetHemp brand in Amazon US and UK. The team at Relevium will be launching five (5) PlanetHemp products in in H2 2018.
Abis Hussain, Senior Marketing Officer at Relevium stated: “We are seeing a huge appetite for hemp nutrition, skin care and hemp derived CBD products selling in legal jurisdictions online, both in the UK and US.” Mr. Hussain continued: “With increasing media exposure and regulatory changes, consumers are looking for hemp-based products to add them to their wellness programs. We feel that we are in the right position to capitalize on this segment.”
Introduction and launch of Heart and Eye Health Omega 7 products
Following the signing of the exclusivity agreement with Tersus for Provinol Ultra-Purified Omega 7products, the Company is in the process of building a premium brand and online assets for a new line of research-based vegan and fish oil based product line. The Omega 7 products for Heart and Vision will be the first of a series of products that will be launched and marketed as a premium product.
Mr. Hussain stated: “Omega products sell extremely well online. We are well positioned with exclusive and premium products like Ultra-Purified Omega 7, and our team is confident that a premium brand strategy will deliver optimal value to Relevium. The new premium brand will allow us to market products to a new demographic and market segment that is diversified from the Bioganix® core brand.”
Guidance on legal hemp derivatives for nutraceutical and skin care
Relevium has seen an increase in online content and traffic for hemp and hemp derivatives such as CBD. The market place is changing fast and the rate of adoption as well. In advance of fully launching products, brands and new business segments, the Company has begun accumulating a portfolio of domain names and is also building online assets for an elevated an trusted brand in the space.
The Company has been actively qualifying various suppliers, vendors, products and research partners in the space and believes that launching products within the legal hemp derivative market in H2 2018 is feasible.
Management is working with its legal counsel to ensure full compliance within a fast-evolving space. In order to ensure compliance for online retail, the company has engaged experts to build a private Blockchain with the objective of supporting and ensuring compliance in the entire supply chain.
Mr. Useche stated: “We have been actively monitoring and working in this market. We are cognisant that e-commerce for hemp and hemp derivatives for over-the-counter and prescription formulations will be an enormous market. We believe to have the initial based to ensure we position an elevated, trusted and compliant Relevium brand in this space.”
Execution of product launches in the hemp, hemp derivatives including CBD will be dependent on compliance with laws and regulations in each jurisdiction and each e-commerce platform where products are to be offered.
Launching of first pet care product
Relevium previously announced the creation of a segment of pet-focused products. The Company expects to launch its first products to include research-based joint and brain health formulations, both products currently trending online in 2018.
European expansion of Bioganix brand
The Company has been working on building out distribution for the European Union (“E.-U.”), notably in the United Kingdom, Germany, France, Spain and Italy. Initially focused on the geographical expansion of the BioGanix brand, Relevium will launch brands and products in the E.-U. as permitted by law.
Strategy and guidance for actionable M&A opportunities
The Company’s acquisition strategy is now focused on three main parameters: (1) strategic fit, (2) diversification and (3) accionability, the latter greatly dependent on market conditions, deal structure and our own valuation in the market. The main objective is ensure that we deliver a target that adds value to the portfolio and is well structured to limit the dilution effect.
The pipeline for acquisitions has been as high as USD 120,000,000 in cash flows to acquire. Depending on marketplace fluctuations, the pipeline is rarely lower than USD 50,000,000 in cash flow to acquire.
Mr. Useche stated: “The acquisition parameters from inception have been clear: we want to buy assets with high margins and pay low multiples, but there must be strategic fit and brand value add to our current business. We remain very active and in discussions but have yet to find the perfect candidate for our second acquisition that meets our more stringent selection process.”
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will obtain stock exchange approval of the Offering, the proposed acquisition will occur as anticipated, that the Company will raise sufficient funds, and that the Company will obtain all requisite approvals of the acquisition. These forward- looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed acquisitions may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds under the Offering. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche
President and CEO
Relevium Technologies Inc.
+1.888.528.8687
investors@releviumcorp.com
www.releviumtechnologies.com
- Published in Relevium Technologies